{"id":13858,"date":"2011-06-14T10:30:00","date_gmt":"2011-06-14T08:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/novo-nordisk-paga-267-mln-dollari-per-risolvere-cause-usa\/"},"modified":"2011-06-14T10:30:00","modified_gmt":"2011-06-14T08:30:00","slug":"novo-nordisk-paga-267-mln-dollari-per-risolvere-cause-usa","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/novo-nordisk-paga-267-mln-dollari-per-risolvere-cause-usa\/","title":{"rendered":"Novo Nordisk pays $26.7 million to settle US lawsuits"},"content":{"rendered":"

Novo Nordisk announced it has reached an agreement with the US Justice Department and two citizens to settle an investigation into alleged unfair trade practices regarding the anti-bleeding drug NovoSeven, which was allegedly the object of improper promotion for unapproved uses: under the agreement, Novo Nordisk, which denies all charges, will pay $ 25 million to settle the case, a company statement announced. <\/p>\n

<\/font><\/font><\/span><\/p>\n

The company added that it "does not recommend or promote 'off-label' use of the drugs and in fact actively works with the FDA to address safety concerns when physicians, exercising their professional judgment, use NovoSeven outside the approved indications." <\/p>\n

<\/font><\/font><\/span><\/p>\n

Novo Nordisk also agreed to pay just over $1.7 million to the US government to settle allegations of fraudulent practices to be included in the Medicaid program. The accusation concerns the marketing of the insulin-based products Novolin and Novolog: it seems that some scientific representatives of the drug Novo Nordisk paid pharmacists to recommend the medicines and had access to confidential information on the patients. Again, Novo denies all allegations.<\/p>\n

<\/font><\/font><\/span><\/p>\n

June 14, 2011 \u2013 Pharmakronos<\/p>\n

<\/font><\/span><\/em><\/p>","protected":false},"excerpt":{"rendered":"

Novo Nordisk ha annunciato di aver raggiunto un accordo con il dipartimento di Giustizia Usa e con due cittadini per dirimere un’indagine relativa a presunte pratiche commerciali scorrette per quanto riguarda il medicinale antiemorragico NovoSeven, che sarebbe stato oggetto di promozione impropria su usi non approvati: in base all’accordo Novo Nordisk, che respinge ogni addebito, …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-13858","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13858","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=13858"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13858\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=13858"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=13858"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=13858"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}